advanced search

Cristal Therapeutics

Cristal Therapeutics logo

Cristal Therapeutics is a clinical-stage business with a pipeline of proprietary drug candidates based on its nanoparticle technology platform, CriPec®, for enhancing and enabling the targeted delivery of injectables in various therapeutic areas including oncology.


Visit Website

HEADQUARTERS
Cristal Therapeutics
Oxfordlaan 55
6229 EV Maastricht
The Netherlands

Phone / Contact

T: +31 433 88 58 68
E: [email protected]

Connect

Cristal Therapeutics is a clinical-stage pharmaceutical company developing targeted nanomedicines with superior therapeutic profiles for the treatment of cancer and other diseases. Its product candidates, based on the proprietary polymeric nanoparticle technoloy, CriPec®, are rationally designed to target specific tissue, cells and intracellular components, and to have a defined duration at disease sites.

It’s lead candidate, a CriPec® formulation of docetaxel, is in Phase II clinical trials for the treatment of solid tumours.

Cristal Therapeutics was founded in 2011 as a spin-off from Utrecht University, The Netherlands. It is privately held, having raised more than €30 million from private investors.

Authors and Contacts

Dr Cristianne Rijcken
Founder & Chief Scientific Officer
Cristal Therapeutics

Article

INJECTION
Dr Cristianne Rijcken
COMPANY SHOWCASE: Cristal Therapeutics
Over the past year, Cristal Therapeutics has transitioned from a research-stage start-up to a fully fledged, clinical-stage business with a promising pipeline of proprietary drug candidates. This diverse pipeline together with the proprietary nanoparticle platform, CriPec®, presents a broad range of promising late- and early-stage partnering opportunities for companies active in the oncology space.
Top